ABVC BioPharma (ABVC) Stock Price, News & Analysis

Company Overview

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens. ABVC BioPharma applies its platform to generate both personalized and off-the-shelf candidates, with preclinical and early-stage clinical studies evaluating safety, immunogenicity and preliminary efficacy.

Headquartered in Research Triangle Park, North Carolina, ABVC BioPharma operates research laboratories in North America and collaborates with academic and industry partners to advance its development programs. The company’s leadership team is composed of executives and scientists with experience in peptide chemistry, immunology and clinical development, guiding its efforts to bring new vaccine-based therapies to market.

Key Stats

• Today's Range: $1.02 to $1.09
• 50-Day Range: $0.91 to $1.48
• 52-Week Range: $0.88 to $5.48
• Volume: 78,525 shs
• Average Volume: 114,936 shs
• Market Capitalization: $26.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

ABVC BioPharma Stock Analysis - MarketRank™

ABVC BioPharma scored higher than 5% of companies evaluated by MarketBeat, and ranked 840th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

ABVC BioPharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

ABVC BioPharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of ABVC BioPharma is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ABVC BioPharma is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ABVC BioPharma has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.43% of the float of ABVC BioPharma has been sold short.

Short Interest Ratio / Days to Cover

ABVC BioPharma has a short interest ratio ("days to cover") of 1.34, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ABVC BioPharma has recently increased by 11.31%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ABVC BioPharma does not currently pay a dividend.

Dividend Growth

ABVC BioPharma does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added ABVC BioPharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ABVC BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.00% of the stock of ABVC BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

11.38% of the stock of ABVC BioPharma is held by institutions.

ABVC Stock Analysis - Frequently Asked Questions

How have ABVC shares performed this year?

ABVC BioPharma's stock was trading at $2.13 at the beginning of the year. Since then, ABVC stock has decreased by 51.6% and is now trading at $1.03.

How were ABVC BioPharma's earnings last quarter?

ABVC BioPharma, Inc. (NASDAQ:ABVC) issued its earnings results on Tuesday, March, 3rd. The company reported ($0.11) EPS for the quarter.

When did ABVC BioPharma's stock split?

ABVC BioPharma shares reverse split on the morning of Tuesday, July 25th 2023.The 1-10 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did ABVC BioPharma IPO?

ABVC BioPharma (ABVC) raised $7 million in an initial public offering (IPO) on Tuesday, August 3rd 2021. The company issued 1,100,000 shares at $6.25 per share.

How do I buy shares of ABVC BioPharma?

Shares of ABVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ABVC BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ABVC BioPharma investors own include Meta Platforms (META), NIO (NIO), ObsEva (OBSV), Tesla (TSLA), Alibaba Group (BABA), ChargePoint (CHPT) and Walt Disney (DIS).

Company Calendar

• Last Earnings: 3/03/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ABVC
• CIK: 1173313
• Web: www.abvcpharma.com
• Phone: (510)-668-0881
• Fax: N/A
• Employees: 30
• Year Founded: 2002

Profitability

• EPS (Trailing Twelve Months): ($0.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.91 million
• Net Margins: N/A
• Pretax Margin: -768.55%
• Return on Equity: -65.11%
• Return on Assets: -40.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.41
• Quick Ratio: 0.41

Sales & Book Value

• Annual Sales: $510 thousand
• Price / Sales: 51.38
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.52 per share
• Price / Book: 1.98

Miscellaneous

• Outstanding Shares: 25,440,000
• Free Float: 20,606,000
• Market Cap: $26.20 million
• Optionable: Not Optionable
• Beta: 0.42